Skip to main content

Overview

Dr. Schackman is the Director of CHERISH – The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV - a multi-institutional Center of Excellence, funded by the National Institute on Drug Abuse (P30DA040500). CHERISH is a collaboration among researchers at Weill Cornell Medicine, Boston Medical Center, the University of Pennsylvania Leonard Davis Institute of Health Economics, and the University of Miami Miller School of Medicine. Dr. Schackman is the Saul P. Steinberg Distinguished Professor of Healthcare Policy & Research at Weill Cornell, where he conducts economic evaluations of the comparative effectiveness of health interventions alongside clinical trials and cohort studies, cost-effectiveness and comparative effectiveness simulation modeling studies, and implementation science studies—particularly relating to treatment of infectious diseases and substance use disorders. His current research includes economic evaluations of HIV and hepatitis C screening and treatment in substance use treatment settings, and economic evaluations of treatments for opioid use disorder. 

Highlights

  1. 1
    JAMA network open · 2024
    PMID: 38980680PMCID: PMC11234232DOISenior author4 citations
  2. 2
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021
    PMID: 34243831PMCID: PMC8591614DOI36 citations
  3. 3
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025
    PMID: 41271095PMCID: PMC13148418DOI

Publications

239 publications

Active

8 grants
  • Co-I
    Columbia University-Weill Cornell Medicine CFAR (CU-WCM CFAR)
    National Institute of Allergy and Infectious Diseases · 2026–2031 · via Columbia University
  • PI
    Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation
    National Institute on Drug Abuse · 2015–2030· 6 renewals
  • Co-I
    Reversing Overdose Epidemics through Simulation, Collaboration, and Unified Efforts (RESCUE)
    National Institute on Drug Abuse · 2024–2028 · via University of Minnesota
  • PI
    HEAL Data2Action Modeling and Economic Resource Center
    National Institute on Drug Abuse · 2022–2027
  • Sub-PI
    Miami Dade County ASsessment of Phylogenics to Improve Resource Equity: MD ASPIRE
    National Institute of Mental Health · 2022–2027 · via University of California, San Diego
  • Sub-PI
    Accelerating Implementation of Multilevel-strategies to Advance Long Acting Injectables for Underserved Populations (The ALAI UP Project)
    Health Resources and Services Administration · 2024–2026 · via Columbia University
    6 U1SHA46532-03-01
  • Co-I
    CDC Overdose Data to Action: Local
    Fund for Public Health in New York, Inc. · 2023–2026Contract
    SA 241817-01
  • Co-I
    Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
    National Institute of Diabetes and Digestive and Kidney Diseases · 2020–2026
Completed grants (38)
  • Co-I
    Reducing Post-Hospital Mortality in HIV-Infected Adults in Tanzania
    National Institute of Mental Health · 2018–2025
  • Sub-PI
    CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York State
    National Institute on Drug Abuse · 2019–2025 · via Columbia University
  • PI
    DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)
    National Institute on Drug Abuse · 2019–2025
  • Co-I
    Health and Economic Outcomes of Treatment with Extended-Release Naltrexone Among Pre-Release Prisoners with Opioid Use Disorder
    National Institute on Drug Abuse · 2019–2025
  • PI
    Simulation Modeling To Support The Public Health Response To The Opioid Crisis In North America
    National Institute on Drug Abuse · 2021–2024
  • PI
    DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs
    National Institute on Drug Abuse · 2009–2024· 5 renewals
  • MPI
    A Multi-Site Multi-Setting RCT of Integrated HIV Prevention and HCV Care for PWID
    National Institute on Drug Abuse · 2017–2024 · via Columbia University
  • MPI
    Impact of Jail-Based Methadone on Overdose, Recidivism, HIV, and Health Outcomes and Costs in New York City, 2011-2017
    National Institute on Drug Abuse · 2018–2024 · via New York University School of Medicine (Grossman)
  • Sub-PI
    Addiction Health Services Research Conference
    National Institute on Drug Abuse · 2023–2024 · via University of Wisconsin
  • Sub-PI
    HEALing Communities Study: Data Coordinating Center
    National Institute on Drug Abuse · 2019–2024 · via RTI International· 2 renewals
  • Sub-PI
    A pragmatic trial of two strategies for implementing an effective eHealth HIV prevention program
    National Institute of Mental Health · 2018–2023 · via Northwestern University
  • MPI
    Researching Effective Strategies to Prevent Opioid Death (RESPOND)
    National Institute on Drug Abuse · 2018–2023 · via Boston Medical Center (Corporation)
  • Co-I
    Expanding FDA's Opioids Systems Model to Enable Economic Evaluations and Outcome Analyses of National Opioid Policies
    United States Food & Drug Administration · 2020–2022 · via The General Hospital Corporation (dba Massachusetts General Hospital)
  • Co-I
    FANMI: Community Cohort Care for HIV-infected Adolescent Girls in Haiti
    Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2017–2022
  • Sub-PI
    A Cluster RCT to Increase HIV Testing in Substance Use Treatment Programs
    National Institute on Drug Abuse · 2016–2022 · via Columbia University
  • Co-I
    PRimary care Opioid Use Disorders Treatment (PROUD) Trial
    National Institute on Drug Abuse · 2019–2022 · via Kaiser Foundation Research Institute
  • Sub-PI
    Evaluation of Community-based Drug User Health Hubs to Reduce Opioid Overdoses in NY State
    Centers for Disease Control and Prevention · 2018–2022 · via Health Research INC (Center for Community Health)
  • Sub-PI
    Localized Economic Modeling to Optimize Public Health Strategies for HIV treatment and Prevention
    National Institute on Drug Abuse · 2016–2021 · via Simon Fraser University
  • PI
    Economic Evaluation of Medication-Assisted Substance Abuse Treatment
    National Institute on Drug Abuse · 2014–2020
  • KP
    Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit
    National Institute of Allergy and Infectious Diseases · 2013–2020
  • Co-I
    Conditional M. Tuberculosis Knockdown Mutants for TB Drug Development
    Bill & Melinda Gates Foundation · 2017–2020
    BMGF OPP1024065
  • PI
    Enhanced Access to HIV Care for Drug Users in San Juan, Puerto Rico
    National Institute on Drug Abuse · 2013–2020
  • Sub-PI
    HealthCall: Enhancing Brief Intervention for HIV Primary Care Alchohol Dependence
    National Institute on Alcohol Abuse and Alcoholism · 2014–2019 · via Research Foundation for Mental Hygiene, Inc.
  • MPI
    The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials Network
    National Institute on Drug Abuse · 2015–2019 · via University of Miami
  • PI
    Consulting Agreement Amendment (Term Extension for Zack Rosen)
    OneGreenOak, LLC · 2018–2019Contract
    SA 184128-01
  • PI
    Consulting Agreement Amendment No. 1 (Term extension)
    John Mordecai · 2018–2019Contract
    SA 184127-01
  • Sub-PI
    Cost-Effectiveness of Preventing HIV Complications
    National Institute of Allergy and Infectious Diseases · 2010–2018 · via The General Hospital Corporation (dba Massachusetts General Hospital)· 2 renewals
  • Sub-PI
    Project INSPIRE-NYC
    Centers for Medicare & Medicaid Services · 2014–2018 · via Fund for Public Health in New York, Inc.
    5 C1 CMS331330-04
  • PI
    Supervised Injection Facility Feasibility Study
    Fund for Public Health in New York, Inc. · 2017–2017Contract
    FPHNY SA
  • Sub-PI
    Intensive Models of HCV Care for Injection Drug Users
    National Institute on Drug Abuse · 2012–2017 · via Yeshiva University
  • Sub-PI
    Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
    National Institute on Drug Abuse · 2012–2016 · via The General Hospital Corporation (dba Massachusetts General Hospital)
  • PI
    Quality of Life Outcomes in Prescription and Injection Opioid Dependence
    National Institute on Drug Abuse · 2012–2016
  • KP
    Integrated vs. Separate Care for Hepatitis C, Substance Abuse, and HIV Prevention
    National Institute on Drug Abuse · 2010–2015 · via State University of New York Downstate Medical Center
  • MPI
    HPTN 065 HIV Testing Cost Analysis
    National Institutes of Health · 2013–2014 · via Family Health International
  • KP
    Haiti AIDS Research Training: Models to Implementation
    Fogarty International Center · 2009–2014 · via GHESKIO Centers
  • Sub-PI
    Modeling the Impact of HIV Prevention Interventions
    National Institute of Mental Health · 2010–2014 · via Harvard University
  • Sub-PI
    Pharmacogenomics of HIV Therapy
    National Institute of Allergy and Infectious Diseases · 2009–2013 · via Vanderbilt University
  • PI
    HCV Treatment Cost-Effectiveness in 3 IDU Populations
    NIDA · 2004–2010 · via NIH RePORTER

Clinical research

2 studies
Completed & closed trials (2)
  • PI
    Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
  • PI
    HEALing Communities Study
    Research Triangle Institute · CLOSED TO ACCRUAL (as of 2023)

News mentions

1 MD student · 2 Postdocs · 9 other

External relationships

Other

Simon Fraser University